{"contentid": 488396, "importid": NaN, "name": "US FDA pauses work on Anixa's novel CAR-T cell candidate", "introduction": "Anixa Biosciences has been subjected to a clinical trial hold for a CAR-T cell therapy being developed in partnership with the Moffitt Cancer Center (MCC).", "content": "<p>Anixa Biosciences (Nasdaq: ANIX) has been subjected to a clinical trial hold for a CAR-T cell therapy being developed in partnership with the Moffitt Cancer Center (MCC).</p>\n<p>Shares in the company, which is focused on the treatment and prevention of cancer and infectious diseases, fell over 10% following the announcement.</p>\n<p>The study under the Investigational New Drug (IND) application has been stopped pending submission of additional information requested by the Food and Drug Administration.</p>\n<p>In a statement, Anixa said it expected the FDA to provide a letter to MCC with further details including the specific information it requires before continuing its review of the IND.</p>\n<p>The MCC will assemble and submit information addressing the request &ldquo;as soon as possible thereafter.&rdquo;</p>\n<h2>Anixa progress</h2>\n<p>Anixa is working on a therapy comprised of engineered T cells that target the follicle stimulating hormone receptor (FSHR).</p>\n<p>Since the target is a hormone receptor, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T.</p>\n<p>The firm has also established a strategic alliance and license agreement with the Cleveland Clinic for an innovative breast cancer vaccine technology.</p>\n<p>In addition, since 2019, the company has been working with the Wistar Institute, in Pennsylvania, USA, on myeloid-derived suppressor cell (MDSC) biology.</p>\n<p>Commenting on the recent trial hold, Anixa chief executive Amit Kumar said: \"We are eagerly awaiting guidance from the FDA with details about the specific information requested to clear the IND, enabling initiation of clinical trials.\"</p>", "date": "2021-04-20 11:06:00", "meta_title": NaN, "meta_keywords": "Anixa, therapy, CAR-T, clinical, trial, hold, cell, cancer, information, places, Center, subjected, Moffitt, partnership, developed, Biosciences, receptor", "meta_description": "Anixa Biosciences has been subjected to a clinical trial hold for a CAR-T cell therapy being developed in partnership with Moffitt Cancer Center (MCC).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-20 10:44:22", "updated": "2021-04-20 11:09:30", "access": NaN, "url": "https://www.thepharmaletter.com/article/us-fda-places-clinical-trial-hold-on-anixa-s-novel-car-t-cell-therapy", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "anixa_large.png", "image2id": "anixa_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "USA", "company_tag": "Anixa Biosciences, Moffitt Cancer Center (MCC)", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-20 11:06:00"}